Literature DB >> 21393859

Hunk is required for HER2/neu-induced mammary tumorigenesis.

Elizabeth S Yeh1, Thomas W Yang, Jason J Jung, Heather P Gardner, Robert D Cardiff, Lewis A Chodosh.   

Abstract

Understanding the molecular pathways that contribute to the aggressive behavior of human cancers is a critical research priority. The SNF1/AMPK-related protein kinase Hunk is overexpressed in aggressive subsets of human breast, ovarian, and colon cancers. Analysis of Hunk(–/–) mice revealed that this kinase is required for metastasis of c-myc–induced mammary tumors but not c-myc–induced primary tumor formation. Similar to c-myc, amplification of the proto-oncogene HER2/neu occurs in 10%–30% of breast cancers and is associated with aggressive tumor behavior. By crossing Hunk(–/–) mice with transgenic mouse models for HER2/neu-induced mammary tumorigenesis, we report that Hunk is required for primary tumor formation induced by HER2/neu. Knockdown and reconstitution experiments in mouse and human breast cancer cell lines demonstrated that Hunk is required for maintenance of the tumorigenic phenotype in HER2/neu-transformed cells. This requirement is kinase dependent and resulted from the ability of Hunk to suppress apoptosis in association with downregulation of the tumor suppressor p27(kip1). Additionally, we find that Hunk is rapidly upregulated following HER2/neu activation in vivo and in vitro. These findings provide what we believe is the first evidence for a role for Hunk in primary tumorigenesis and cell survival and identify this kinase as an essential effector of the HER2/neu oncogenic pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21393859      PMCID: PMC3049391          DOI: 10.1172/JCI42928

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  97 in total

1.  Regulation of SNARK activity in response to cellular stresses.

Authors:  Diana L Lefebvre; Cheryl F Rosen
Journal:  Biochim Biophys Acta       Date:  2005-04-08

2.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors:  Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.

Authors:  Ioanna G Maroulakou; William Oemler; Stephen P Naber; Philip N Tsichlis
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

4.  Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.

Authors:  S Cariou; J C Donovan; W M Flanagan; A Milic; N Bhattacharya; J M Slingerland
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

5.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.

Authors:  Russell G Jones; David R Plas; Sara Kubek; Monica Buzzai; James Mu; Yang Xu; Morris J Birnbaum; Craig B Thompson
Journal:  Mol Cell       Date:  2005-04-29       Impact factor: 17.970

Review 6.  The EGF receptor family as targets for cancer therapy.

Authors:  J Mendelsohn; J Baselga
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

Review 7.  Regulation of the cdk inhibitor p27 and its deregulation in cancer.

Authors:  J Slingerland; M Pagano
Journal:  J Cell Physiol       Date:  2000-04       Impact factor: 6.384

8.  Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis.

Authors:  Nathalie Dourdin; Babette Schade; Robert Lesurf; Michael Hallett; Robert J Munn; Robert D Cardiff; William J Muller
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

9.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.

Authors:  Jason I Herschkowitz; Karl Simin; Victor J Weigman; Igor Mikaelian; Jerry Usary; Zhiyuan Hu; Karen E Rasmussen; Laundette P Jones; Shahin Assefnia; Subhashini Chandrasekharan; Michael G Backlund; Yuzhi Yin; Andrey I Khramtsov; Roy Bastein; John Quackenbush; Robert I Glazer; Powel H Brown; Jeffrey E Green; Levy Kopelovich; Priscilla A Furth; Juan P Palazzo; Olufunmilayo I Olopade; Philip S Bernard; Gary A Churchill; Terry Van Dyke; Charles M Perou
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

10.  An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.

Authors:  Andrea H Bild; Joel S Parker; Adam M Gustafson; Chaitanya R Acharya; Katherine A Hoadley; Carey Anders; P Kelly Marcom; Lisa A Carey; Anil Potti; Joseph R Nevins; Charles M Perou
Journal:  Breast Cancer Res       Date:  2009-07-28       Impact factor: 6.466

View more
  16 in total

Review 1.  Hormonally up-regulated neu-associated kinase: A novel target for breast cancer progression.

Authors:  Joelle N Zambrano; Benjamin A Neely; Elizabeth S Yeh
Journal:  Pharmacol Res       Date:  2017-02-09       Impact factor: 7.658

2.  Gene loci associated with insulin secretion in islets from non-diabetic mice.

Authors:  Mark P Keller; Mary E Rabaglia; Kathryn L Schueler; Donnie S Stapleton; Daniel M Gatti; Matthew Vincent; Kelly A Mitok; Ziyue Wang; Takanao Ishimura; Shane P Simonett; Christopher H Emfinger; Rahul Das; Tim Beck; Christina Kendziorski; Karl W Broman; Brian S Yandell; Gary A Churchill; Alan D Attie
Journal:  J Clin Invest       Date:  2019-07-25       Impact factor: 14.808

Review 3.  Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.

Authors:  Elizabeth A Fry; Pankaj Taneja; Kazushi Inoue
Journal:  Int J Cancer       Date:  2016-09-12       Impact factor: 7.396

Review 4.  Strategies for the discovery and development of therapies for metastatic breast cancer.

Authors:  Bedrich L Eckhardt; Prudence A Francis; Belinda S Parker; Robin L Anderson
Journal:  Nat Rev Drug Discov       Date:  2012-06-01       Impact factor: 84.694

Review 5.  Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.

Authors:  Huiping Shi; Weili Zhang; Qiaoming Zhi; Min Jiang
Journal:  Tumour Biol       Date:  2016-10-10

6.  Bisphenol A Disrupts HNF4α-Regulated Gene Networks Linking to Prostate Preneoplasia and Immune Disruption in Noble Rats.

Authors:  Hung-Ming Lam; Shuk-Mei Ho; Jing Chen; Mario Medvedovic; Neville Ngai Chung Tam
Journal:  Endocrinology       Date:  2015-10-23       Impact factor: 4.736

7.  Hunk negatively regulates c-myc to promote Akt-mediated cell survival and mammary tumorigenesis induced by loss of Pten.

Authors:  Elizabeth S Yeh; George K Belka; Ann E Vernon; Chien-Chung Chen; Jason J Jung; Lewis A Chodosh
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-21       Impact factor: 11.205

8.  PRG2 and AQPEP are misexpressed in fetal membranes in placenta previa and percreta†.

Authors:  Elisa T Zhang; Roberta L Hannibal; Keyla M Badillo Rivera; Janet H T Song; Kelly McGowan; Xiaowei Zhu; Gudrun Meinhardt; Martin Knöfler; Jürgen Pollheimer; Alexander E Urban; Ann K Folkins; Deirdre J Lyell; Julie C Baker
Journal:  Biol Reprod       Date:  2021-07-02       Impact factor: 4.285

9.  Hunk/Mak-v is a negative regulator of intestinal cell proliferation.

Authors:  Karen R Reed; Igor V Korobko; Natalia Ninkina; Elena V Korobko; Ben R Hopkins; James L Platt; Vladimir Buchman; Alan R Clarke
Journal:  BMC Cancer       Date:  2015-03-08       Impact factor: 4.430

10.  Identification of Nedd4 E3 ubiquitin ligase as a binding partner and regulator of MAK-V protein kinase.

Authors:  Svetlana V Kalinichenko; Keiji Itoh; Elena V Korobko; Sergei Y Sokol; Vladimir L Buchman; Igor V Korobko
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.